Safety and Usefulness of Intracoronary Acetylcholine 200 μg Into the Left Coronary Artery as Vasoreactivity Testing: Comparisons With Intracoronary Acetylcholine Maximum 100 μg
Clinical Cardiology · 2024
DOI: 10.1002/clc.70001 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Shozo Sueda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Minami Matsuyama Hospital, Matsuyama, Japan. Hauptthemen laut MEDLINE: Acetylcholine, Coronary Vessels, Coronary Vasospasm, Injections, Intra-Arterial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Objectives
We retrospectively analyzed the usefulness and safety of intracoronary acetylcholine (ACh) 200 μg into the left coronary artery (LCA) as vasoreactivity testing compared with intracoronary ACh 100 μg.
Methods
We recruited 1433 patients who had angina‐like chest pain and intracoronary ACh testing in the LCA, including 1234 patients with a maximum ACh 100 μg and 199 patients with a maximum ACh 200 μg. ACh was injected in incremental doses of 20/50/100/200 μg into the LCA. Positive spasm was defined as ≥ 90% stenosis, usual chest pain, and ischemic electrocardiogram (ECG) changes.
Results
The incidence of coronary constriction ≥ 90%, usual chest pain, and ischemic ECG changes with a maximum ACh of 100 μg was markedly higher than that with a maximum ACh of 200 μg. The frequency of unusual chest pain in patients with a maximum ACh of 200 μg was higher than that in those with a maximum ACh of 100 μg (13% vs. 3%, p < 0.001). In patients with rest angina, positive spasm of maximum ACh 100 μg was significantly higher than that of maximum ACh 200 μg, whereas there was no difference regarding positive spasm in patients with atypical chest pain between the two ACh doses. Major complications (1.38% vs. 1.51%, p = 0.8565) and the occurrence of paroxysmal atrial fibrillation (1.81% vs. 2.63%, p = 0.6307) during ACh testing in the LCA were not different between the two maximum ACH doses.
Conclusions
Intracoronary ACh 200 μg into the LCA is clinically useful and safe for vasoreactivity testing when intracoronary ACh 100 μg dose not provoke spasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Minami Matsuyama Hospital, Matsuyama, Japan.
- Department of Cardiology, Ehime Prefectural Niihama Hospital, Niihama, Japan.
- Department of Cardiology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Sueda, S., Hayashi, Y., Ono, H., Sakaue, T., & Ikeda, S. (2024). Safety and Usefulness of Intracoronary Acetylcholine 200 μg Into the Left Coronary Artery as Vasoreactivity Testing: Comparisons With Intracoronary Acetylcholine Maximum 100 μg. Clinical Cardiology. https://doi.org/10.1002/clc.70001
Vancouver
Sueda S, Hayashi Y, Ono H, Sakaue T, Ikeda S. Safety and Usefulness of Intracoronary Acetylcholine 200 μg Into the Left Coronary Artery as Vasoreactivity Testing: Comparisons With Intracoronary Acetylcholine Maximum 100 μg. Clinical Cardiology. 2024. doi:10.1002/clc.70001
BibTeX
@article{Sueda2024,
author = {Sueda, Shozo and Hayashi, Yutaka and Ono, Hiroki and Sakaue, Tomoki and Ikeda, Shuntaro},
title = {Safety and Usefulness of Intracoronary Acetylcholine 200 μg Into the Left Coronary Artery as Vasoreactivity Testing: Comparisons With Intracoronary Acetylcholine Maximum 100 μg},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.70001}
}
EUVIMED